NUS Stock Analysis: Nu Skin Enterprises | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 254m USD | 12M Return: -40.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.09M
Qual. Beats: 0
Rev. Trend: -99.6%
Qual. Beats: -3
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nu Skin Enterprises is a global beauty and wellness company that develops and distributes skin care devices, cosmetics, personal care products, and nutritional supplements under the Nu Skin, Pharmanex, and ageLOC brands. Its product line includes the ageLOC LumiSpa family, ageLOC TruFace, Nutricentials, Prysm iO, and wellness offerings such as LifePak, ageLOC TRME, and Beauty Focus. The company also conducts in-house research and product development across skin care, supplements, and connected device categories.
The business relies primarily on a direct selling model, distributing through independent sales representatives and marketers in addition to retail stores, websites, and digital platforms. This multilevel marketing approach is a common structure in the personal care and supplement industry, allowing the company to scale a global salesforce without traditional retail infrastructure. Asia-Pacific is the companys core geographic market, with Mainland China, South Korea, and Southeast Asia as key regions, followed by the Americas, Japan, Hong Kong/Taiwan, and Europe & Africa. Founded in 1984 and headquartered in Provo, Utah, Nu Skin trades on the NYSE under the ticker NUS and is classified within the GICS Consumer Staples sector and Personal Care Products sub-industry.
- China direct selling regulations threaten Mainland China revenue
- LumiSpa device and TRME wellness sales drive segment margin recovery
- US dollar strength pressures translated revenue across Asian markets
| Net Income: 54.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.72 > 1.0 |
| NWC/Revenue: 18.45% < 20% (prev 15.75%; Δ 2.69% < -1%) |
| CFO/TA 0.06 > 3% & CFO 76.0m > Net Income 54.5m |
| Net Debt (131.2m) to EBITDA (129.5m): 1.01 < 3 |
| Current Ratio: 2.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.4m) vs 12m ago -1.80% < -2% |
| Gross Margin: 69.31% > 18% (prev 67.57%; Δ 1.73% > 0.5%) |
| Asset Turnover: 104.1% > 50% (prev 120.7%; Δ -16.56% > 0%) |
| Interest Coverage Ratio: 5.30 > 6 (EBIT TTM 79.1m / Interest Expense TTM 14.9m) |
| A: 0.19 (Total Current Assets 522.9m - Total Current Liabilities 257.0m) / Total Assets 1.38b |
| B: 1.35 (Retained Earnings 1.86b / Total Assets 1.38b) |
| C: 0.06 (EBIT TTM 79.1m / Avg Total Assets 1.38b) |
| D: 1.36 (Book Value of Equity 794.1m / Total Liabilities 582.7m) |
| Altman-Z'' = 7.48 = AAA |
| DSRI: 0.93 (Receivables 45.0m/56.6m, Revenue 1.44b/1.68b) |
| GMI: 0.98 (GM 67.57% / 69.31%) |
| AQI: 1.00 (AQ_t 0.29 / AQ_t-1 0.29) |
| SGI: 0.86 (Revenue 1.44b / 1.68b) |
| TATA: -0.02 (NI 54.5m - CFO 76.0m) / TA 1.38b) |
| Beneish M = -3.21 (Cap -4..+1) = AA |
As of July 15, 2026, the stock is trading at USD 4.97 with a total of 636,087 shares traded. Over the past week, the price has changed by -3.87%, over one month by -3.50%, over three months by -35.14% and over the past year by -40.92%.
Current recommended Stop Loss: 4.70 (which is 5.4% or 1.2 ATR below the current price).
Nu Skin Enterprises has no consensus analysts rating.
| Analysts Target Price | 7.5 | 50.9% |
P/E Trailing = 4.8426
P/E Forward = 5.2301
P/S = 0.1762
P/B = 0.3198
P/EG = 0.7782
Revenue TTM = 1.44b USD
EBIT TTM = 79.1m USD
EBITDA TTM = 129.5m USD
Long Term Debt = 203.6m USD (from longTermDebt, last quarter)
Short Term Debt = 20.0m USD (from shortTermDebt, last quarter)
Debt = 331.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 54.0m
Net Debt = 131.2m USD (calculated: Debt 331.6m - CCE 200.4m)
Enterprise Value = 385.1m USD (253.9m + Debt 331.6m - CCE 200.4m)
Interest Coverage Ratio = 5.30 (Ebit TTM 79.1m / Interest Expense TTM 14.9m)
EV/FCF = 9.26x (Enterprise Value 385.1m / FCF TTM 41.6m)
FCF Yield = 10.79% (FCF TTM 41.6m / Enterprise Value 385.1m)
FCF Margin = 2.88% (FCF TTM 41.6m / Revenue TTM 1.44b)
Net Margin = 3.78% (Net Income TTM 54.5m / Revenue TTM 1.44b)
Gross Margin = 69.31% ((Revenue TTM 1.44b - Cost of Revenue TTM 442.4m) / Revenue TTM)
Gross Margin QoQ = 66.89% (prev 70.74%)
Tobins Q-Ratio = 0.28 (Enterprise Value 385.1m / Total Assets 1.38b)
Interest Expense / Debt = 4.50% (Interest Expense 14.9m / Debt 331.6m)
Taxrate = 15.06% (9.67m / 64.2m)
NOPAT = 67.2m (EBIT 79.1m * (1 - 15.06%))
Current Ratio = 2.03 (Total Current Assets 522.9m / Total Current Liabilities 257.0m)
Debt / Equity = 0.42 (Debt 331.6m / totalStockholderEquity, last quarter 794.1m)
Debt / EBITDA = 1.01 (Net Debt 131.2m / EBITDA 129.5m)
Debt / FCF = 3.16 (Net Debt 131.2m / FCF TTM 41.6m)
Total Stockholder Equity = 796.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.94% (Net Income 54.5m / Total Assets 1.38b)
RoE = 6.84% (Net Income TTM 54.5m / Total Stockholder Equity 796.7m)
RoCE = 7.91% (EBIT 79.1m / Capital Employed (Equity 796.7m + L.T.Debt 203.6m))
RoIC = 6.29% (NOPAT 67.2m / Invested Capital 1.07b)
WACC = 6.74% (E(253.9m)/V(585.5m) * Re(10.56%) + D(331.6m)/V(585.5m) * Rd(4.50%) * (1-Tc(0.15)))
Discount Rate = 10.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 28.71 | Cagr: -0.05%
[DCF] Terminal Value 73.10% ; FCFF base≈51.3m ; Y1≈45.0m ; Y5≈36.4m
[DCF] Fair Price = 9.32 (EV 583.6m - Net Debt 131.2m = Equity 452.4m / Shares 48.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.01 | # QB: 0
Revenue Correlation: -99.55 | Revenue CAGR: -12.13% | SUE: -1.04 | # QB: -3
EPS current Quarter (2026-06-30): EPS=0.20 | Chg30d=-13.04% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.32 | Chg30d=+10.34% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.00 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=-21.3% | GrowthRev=-4.0%
EPS next Year (2027-12-31): EPS=1.32 | Chg30d=+0.76% | Revisions=+25% | GrowthEPS=+32.0% | GrowthRev=+7.3%